Global Molecular Imaging Agents Market Size By Type (Small Molecules, Peptides), By Application (Oncology, Cardiology), By Region, And Segment Forecasts, 2023 to 2032

The Global Molecular Imaging Agents Market was valued at USD 5.9 billion in 2023 and is projected to reach USD 11.7 billion by 2031, growing at a CAGR of 8.9% during the forecast period from 2023 to 2031. Molecular imaging agents are vital in early disease detection, treatment monitoring, and drug development. The market growth is being fueled by increasing prevalence of chronic diseases, rising demand for personalized medicine, and advancements in imaging technology such as PET, SPECT, and hybrid modalities. The integration of AI and machine learning into imaging diagnostics is also creating new growth avenues.

Drivers:

Increasing Prevalence of Chronic Diseases:

The global rise in cancer, cardiovascular diseases, and neurological disorders is significantly contributing to the demand for molecular imaging agents, which play a crucial role in accurate diagnosis and therapy planning.

Technological Advancements:

Innovations in imaging systems and radiopharmaceutical development, including novel biomarkers and targeted agents, are enhancing imaging precision and broadening clinical applications.

Rising Adoption of Personalized Medicine:

Personalized and precision medicine requires highly specific imaging for individual treatment protocols, driving demand for specialized molecular imaging agents.

Restraints:

High Cost of Imaging Procedures:

Advanced imaging technologies and the production of radiopharmaceuticals are capital-intensive, making the procedures expensive and limiting accessibility, especially in low-income regions.

Regulatory and Compliance Challenges:

Strict regulatory requirements for approval and manufacturing of imaging agents, especially radiotracers, create hurdles for market entry and expansion.

Opportunity:

Growth in Emerging Economies:

Increasing healthcare investments, development of medical infrastructure, and rising awareness about early disease diagnosis in Asia-Pacific and Latin America present significant growth opportunities.

Expansion of Theranostics:

The rise of theranostics, which combines diagnostic imaging with targeted therapy, is expanding the clinical applications of molecular imaging agents, particularly in oncology.

Market by System Type Insights:

By system type, PET (Positron Emission Tomography) imaging agents held the largest market share in 2023. PET offers high-resolution images and better quantification, making it the preferred choice in oncology and neurology. The hybrid imaging agent segment (PET/CT, PET/MRI) is expected to grow rapidly, driven by rising adoption in academic and research settings for multi-modal diagnostics.

Market by End-use Insights:

In 2023, the hospitals and diagnostic imaging centers segment dominated the market, accounting for more than 60% of the global revenue. The growth is attributed to increasing patient footfall, availability of advanced equipment, and skilled professionals. Meanwhile, the research institutes segment is witnessing accelerated growth due to increased funding for disease research and new imaging tracer development.

Market by Regional Insights:

North America held the largest share of the molecular imaging agents market in 2023, owing to strong healthcare infrastructure, extensive R&D activities, and the presence of key pharmaceutical and biotech firms. However, the Asia-Pacific region is projected to register the highest growth during the forecast period due to healthcare modernization, increased cancer screening programs, and growing investments in diagnostic technologies in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the market include GE HealthCare, Siemens Healthineers, Bracco Imaging S.p.A., Lantheus Holdings, Inc., Jubilant Radiopharma, Curium Pharma, Cardinal Health, and Bayer AG. These companies are focusing on expanding their product pipelines, acquiring regulatory approvals for novel tracers, and entering into strategic collaborations to strengthen their global presence.

Key Developments:

2023: GE HealthCare introduced a next-generation PET tracer targeting early Alzheimer’s detection.

2024: Lantheus partnered with a major oncology research center to co-develop PSMA-targeted agents for prostate cancer.

2025: Siemens Healthineers launched a hybrid PET/MRI imaging agent optimized for brain tumor diagnostics.

Scope of Work – Global Molecular Imaging Agents Market

Report Metric Details

Market Size (2023) USD 5.9 billion

Projected Market Size (2031) USD 11.7 billion

CAGR (2023–2031) 8.9%

Market Segments System Type (PET, SPECT, Hybrid), End-use (Hospitals, Imaging Centers, Research Institutes)

Growth Drivers Rising chronic disease burden, demand for personalized medicine, imaging technology advances

Opportunities Emerging markets, expansion of theranostic applications

FAQs:

What is the current market size of the Global Molecular Imaging Agents Market?

The market was valued at USD 5.9 billion in 2023.

What is the major growth driver of the Global Molecular Imaging Agents Market?

The primary growth driver is the increasing prevalence of chronic diseases and the demand for early and precise diagnostics.

Which is the largest region during the forecast period in the Global Molecular Imaging Agents Market?

North America is currently the largest region, while Asia-Pacific is expected to see the fastest growth.

Which segment accounted for the largest market share in the Global Molecular Imaging Agents Market?

PET imaging agents held the largest market share by system type in 2023.

Who are the key market players in the Global Molecular Imaging Agents Market?

Major players include GE HealthCare, Siemens Healthineers, Bracco Imaging, Lantheus Holdings, Curium Pharma, and Bayer AG.